RPGLIFENSERPG Life Sciences Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 27 Jan, 2026 · 19:33 IST

Q3 FY26 PAT falls on exceptional items, 9M PAT up 29%, API division to be transferred

Exceptional ItemPat Growth 25pctResults View source PDFExplain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-6.3%Reaction day
₹2101.00
prior close
₹1995.90
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+2.0%-8.3% vs market
Pharmaceuticals peers, median of 155sector+0.7%-7.0% vs sector

On the reaction day the stock moved 8.3 pts less than Nifty Microcap 250 and 7.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
-2.1
15m
-1.5
30m
-4.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-6.3+2.0-8.3+0.7-7.0
Next day
-5.9+1.6-7.5-0.1-5.8
2d
-4.1+3.5-7.6+0.9-5.0
3d
-5.5+2.2-7.7+0.5-6.0
4d
-6.3+6.0-12.3+3.0-9.3
5d
-6.7+7.4-14.0+3.3-10.0
1w
-6.0+5.5-11.4+2.1-8.1
15d
-6.5+7.1-13.6+3.6-10.1
1m
-13.1+1.3-14.4-0.9-12.2
2m
-11.2-8.1-3.2-10.9-0.3
3m
-3.1+12.1-15.2+4.6-7.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

RPG Life Sciences Q3 FY26 revenue grew 4 percent YoY to Rs 180 crore, but net profit fell to Rs 22.1 crore from Rs 34.9 crore due to Rs 8.4 crore exceptional expense, including Rs 11.1 crore one-time impact from new Labour Codes. For 9M FY26, revenue rose to Rs 531 crore and net profit grew 29 percent to Rs 85.3 crore. The company is transferring its API division to a new wholly owned subsidiary, RPG Active Pharma Limited.

Likely market impact

Q3 hit by one-time Labour Codes expense. 9M PAT growth of 29 percent and API restructuring could support longer-term value.